SALT LAKE CITY, June 22, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), a molecular diagnostics company, today announced it has closed a previously-announced registered offering of 8.9 million units consisting of Class A Units and Class B Units at unit prices of $0.30 and $0.29, respectively. Gross proceeds before expenses from the offering were approximately $2.7 million.

Each Class A Unit consists of one share of common stock and one Series J Warrant. Purchasers of the Series J Warrant are entitled to purchase 2.5 shares of common stock at an exercise price of $0.30 per share, exercisable immediately for a period of 60 days following the date of issuance. Class B Units were offered to purchasers whose purchase of Class A Units would result in an ownership of more than 4.99% or 9.99%, at the purchaser’s election, of the Company’s issued and outstanding common stock following consummation of the offering. Each Class B Unit consists of one pre-funded Series K Warrant and one Series J Warrant. The Series K Warrants are exercisable immediately after issuance and until they are exercised in full thereafter at an exercise price of $0.30 per share, of which $0.29 per share was paid at the closing, with $0.01 per share payable upon exercise of the Series K Warrant.

Roth Capital Partners acted as the exclusive placement agent for the offering. After placement agent fees and estimated offering expenses payable by Great Basin, the Company received net proceeds from the sale of the units of approximately $2.1 million. Great Basin intends to use the net proceeds of the offering to fund research and development, for sales and marketing expenses, the redemption of certain notes, and for general corporate purposes, including working capital.

The units, shares of common stock, Series J Warrants, Series K Warrants and the shares issuable upon exercise of the Series J Warrants and Series K Warrants were offered by Great Basin Scientific, Inc. pursuant to a registration statement on Form S-1, as amended (File No. 333-216045) previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

Forward-Looking Statements
This press release includes forward-looking statements regarding the registered offering and the intended use of proceeds from the offering. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to: market conditions; risks associated with the cash requirements of our business; and other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the Company’s Registration Statement. These forward-looking statements speak only as of the date hereof, and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

CONTACT: Contact:

Betsy Hartman
Great Basin Scientific


You May Also Like

Argos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies

DURHAM, N.C., June 15, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology ...

Cara Therapeutics Reports Third Quarter 2017 Financial Results

STAMFORD, Conn., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology ...